2002
DOI: 10.1159/000052029
|View full text |Cite
|
Sign up to set email alerts
|

Complications of Pancreatic Cancer Resection

Abstract: Pancreatic cancer is a common cause of cancer death in the developed world. Currently, resection is the only chance of long-term survival. The post-operative mortality in nonspecialist centres often exceeds 20% but is around 6% or less in specialist centres. The overall complication rate even in specialist centres is 18–54%. An analysis of eleven large series of pancreatic resections shows an incidence of common complications of 10.4% for fistula, 9.9% for delayed gastric emptying, 4.8% for bleeding, 4.8% for … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

10
98
3
15

Year Published

2003
2003
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 164 publications
(126 citation statements)
references
References 74 publications
(161 reference statements)
10
98
3
15
Order By: Relevance
“…The reported rates of PPH in literature is 5e12%. 17,18 The re-exploration rates was 7%, the most common reason being POPF (3/5 patients). The rates of re-exploration in the range of 4e11% have been reported in different series.…”
mentioning
confidence: 94%
“…The reported rates of PPH in literature is 5e12%. 17,18 The re-exploration rates was 7%, the most common reason being POPF (3/5 patients). The rates of re-exploration in the range of 4e11% have been reported in different series.…”
mentioning
confidence: 94%
“…Although it has a reported incidence varying from 1% to 5-12% (6,15,18), postpancreatectomy intraluminal hemorrahge is considered a therapeutic challenge and presents standardized steps of its management. The associated outcome and mortality after early reoperation is at the moment still at high rates, with incidence fluctuating between 13-60% (23,24,25,26).…”
Section: Discussionmentioning
confidence: 99%
“…Except for preventing perioperative bleeding in pancreatic cancer resections [87], there are no reports related to the use of octreotide/somatostatin in controlling bleeding in cancer patients.…”
Section: Somatostatin Analoguesmentioning
confidence: 99%